FDA Moves To Block Some Compounded GLP-1s—Here’s What It Means For Online Prescriptions

Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and ...
wtvr

FDA says shortage of popular diabetes, weight-loss drugs resolved

There is no longer a shortage for tirzepatide injection, which is known by popular brand names like Mounjaro and Zepbound. The U.S. Food and Drug Administration says the shortage of tirzepatide ...
JD Supra

FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs

On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...
Medscape

FDA Proposes End to Mass GLP-1 Compounding

The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...
RAPS

Recon: FDA says Lilly’s tirzepatide shortage is resolved; Merck’s HIV therapy achieves success in pair of Phase 3 trials

Recon: FDA says Lilly’s tirzepatide shortage is resolved; Merck’s HIV therapy achieves success in pair of Phase 3 trials Welcome to Regulatory Reconnaissance, your regulatory news and intelligence ...
JD Supra

FDA Signals it Has No Appetite to Add Popular GLP-1 Drug Substances to the 503B Bulks List

FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposal would materially limit 503B bulk compounding of these GLP-1 products. Comments on the ...
Hosted on MSN

FDA moves to curb GLP-1 compounding as shortages ease

The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, limiting large-scale compounding of these GLP‑1 drugs now that shortages have largely resolved. The ...
Healio

Off-brand GLP-1s still widely available despite shortage resolutions

Please provide your email address to receive an email when new articles are posted on . Many clinics and medical spas offer compounded semaglutide and tirzepatide. Some facilities supplying these ...
Hosted on MSN

FDA moves to ban large-scale compounding of key GLP-1 drugs

The FDA has proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, ending ...